Accueil » Archives de cet auteur: tifwp (page 3)

Archives de cet auteur: tifwp

Sickle Cell Disease

Imatinib   Update: 14 May 2020 A phase I clinical trial in the US aims to investigate whether imatinib (a SYK tyrosine kinase inhibitor) can reduce the expression of SCD symptoms (e.g. RBC deformability, adhesion / stickiness etc) and thus painful crises in patients with SCD. The hypothesis focuses on ...

Lire la suite...

Apotransferrin

  Update: 31 March 2020 No update available.   Update: 31 January 2020 No update available   Update: 25 November 2019 No update available.   Update: 27 September 2019 No update available   Update: 30 July 2019 No update available.   Update: 30 May 2019  Apotransferrinhas a physiological role in ...

Lire la suite...

International Thalassaemia Day 2019 – Get inspired, get involved!

This is how this year’s voting results were shaped: Universal access to quality thalassaemia healthcare services: Building bridges with and for patients (Winning theme, 196 votes) Patients’ voice at the frontline: Advocating for a better future in thalassaemia care and management (112 votes) The globalization of thalassaemia – Common challenges ...

Lire la suite...

Centres de référence des hémoglobinopathies

C’est l’un des nouveaux projets de la FIT pour l’année 2013 dont l’objectif est de développer une base de données pour les centres de référence des hémoglobinopathies à travers le monde, en cartographiant les services qu’ils fournissent aux patients. Il s’agit d’une extension des informations compilées par le projet ENERCA-3 ...

Lire la suite...

Ferroportin inhibitors

VIT-2763   Update: 31 March 2020 No update available.   Update: 31 January 2020 No update available.   Update: 25 November 2019 No update available.   Update: 27 September 2019 No update available   Update: 30 July 2019 Results announced during 24th Annual Congress of the European Hematology Association show ...

Lire la suite...

SLN-124

SLN-124   Update: 31 March 2020 In a corporate presentation, Silence Therapeutics has identified its 2019 accomplishments as: the initiation of a multi-centred, single blind, randomized Phase Ib clinical trial for assessing safety, tolerability, pharmacodynamics and pharmacokinetics of SLN-124 in patients with NTD β-thalassaemia or HbE/ β-thalassaemia receiving orphan drug ...

Lire la suite...